Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.
Given the increasing incidence of HIV-1 infection world-wide, an affordable, effective vaccine is probably the only way that this virus will be contained. Accordingly, our group is developing an oral prime-boost strategy with the primary goal of eliciting broadly neutralizing antibodies against HIV-1 to provide sterilizing immunity for this virus. Our secondary goal is to elicit broadly cross-reactive anti-viral CD8(+) T cells by this strategy to blunt any breakthrough infections that occur after vaccination of individuals who fail to develop sterilizing immunity. This article describes our progress in the use of the live attenuated intracellular bacteria, Salmonella and Shigella, as oral delivery vehicles for DNA vaccines and the development of conformationally constrained HIV-1 Env immunogens that elicit broadly neutralizing antibodies.
Devico
Anthony L
AL
Division of Vaccine Research, Institute of Human Virology, University of Maryland Biotechnology Institute, 725 W. Lombard Street, Baltimore, MD 21201, USA.
Fouts
Timothy R
TR
Shata
Mohamed T
MT
Kamin-Lewis
Roberta
R
Lewis
George K
GK
Hone
David M
DM
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000284:Administration, Oral; D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology; D015704:CD4 Antigens / Q000737:chemistry / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D007117:Immunization, Secondary; D008253:Macaca mulatta; D051379:Mice; D008958:Models, Molecular; D011487:Protein Conformation; D025941:Protein Interaction Mapping; D017434:Protein Structure, Tertiary; D019713:Receptors, CCR5 / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000276:immunology; D012485:Salmonella typhi / Q000276:immunology; D012486:Salmonella typhimurium / Q000276:immunology; D012763:Shigella flexneri / Q000276:immunology; D014611:Vaccination / Q000379:methods*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
D016915:AIDS Vaccines; D001428:Bacterial Vaccines; D015704:CD4 Antigens; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D019713:Receptors, CCR5; D011993:Recombinant Fusion Proteins; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA